moxifloxacin has been researched along with sb 242235 in 1 studies
| Studies (moxifloxacin) | Trials (moxifloxacin) | Recent Studies (post-2010) (moxifloxacin) | Studies (sb 242235) | Trials (sb 242235) | Recent Studies (post-2010) (sb 242235) |
|---|---|---|---|---|---|
| 3,157 | 552 | 1,690 | 22 | 1 | 8 |
| Protein | Taxonomy | moxifloxacin (IC50) | sb 242235 (IC50) |
|---|---|---|---|
| Heat shock protein beta-1 | Homo sapiens (human) | 0.16 | |
| Protein kinase C beta type | Homo sapiens (human) | 0.017 | |
| Protein kinase C alpha type | Homo sapiens (human) | 0.083 | |
| Mitogen-activated protein kinase 14 | Homo sapiens (human) | 0.0572 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jolivette, LJ; Nagilla, R; Ward, KW | 1 |
1 other study(ies) available for moxifloxacin and sb 242235
| Article | Year |
|---|---|
Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human.
Topics: Administration, Oral; Animals; Area Under Curve; Dogs; Haplorhini; Humans; Models, Statistical; Rats; Software; Species Specificity; Xenobiotics | 2005 |